Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Extensive Stage Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 159Carboplatin 147Cisplatin 130Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 69Docetaxel 62Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33Radiosurgery 26130-nm albumin-bound paclitaxel 26fludarabine 23Ipilimumab 23Radiation 21Magnetic Resonance Spectroscopy 21Irinotecan 21Taxes 20Oxaliplatin 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × gossypol acetic acid × Thoracic × Clear all
NCT00934076 2015-05-08

Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer

University of Alabama at Birmingham

Phase 1 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00544596 2014-04-02

R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
Other solid neoplasmThoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡